# Multimodal Imaging Market

> Multimodal Imaging Market Research Report: Size, Share, Trend Analysis By Imaging Modality (Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), Ultrasound, X-ray), By Applications Area (Oncology, Neurology, Cardiology, Orthopedics, Pediatrics), By End Users (Hospitals, Diagnostic Laboratories, Research Institutions, Outpatient Care Centers), By Technology Type (Software-Based Systems, Hardware-Based Systems, Hybrid Systems), By Procedure Type (Diagnostic Imaging, Therapeutic Imaging, Monitoring Imaging) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 5.28%
- **2025:** USD 4.60 Billion (2025)
- **2035:** USD 7.58 Billion (2035)
- **Key Players:** GE HealthCare, Siemens Healthineers, Philips, Canon Medical Systems, United Imaging Healthcare, Bruker Corporation, Mediso Medical Imaging, Spectrum Dynamics Medical

**Report ID:** MRFR/MED/39014-HCR · **Pages:** 100 · **Author:** Rahul Gotadki & Snehal Singh · **Last Updated:** August 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/multimodal-imaging-market-41061

---

## Market Summary

## Multimodal Imaging Market Summary

The multimodal imaging market stood at USD 4.60 billion in 2025 and is projected to reach USD 4.83 billion in 2026 before climbing to USD 7.58 billion by 2035, registering a CAGR of 5.28% over the forecast period. Health systems worldwide are channeling capital toward hybrid [diagnostic imaging](https://www.marketresearchfuture.com/reports/diagnostic-imaging-market-6765) platforms that fuse anatomical detail with functional data, driven by national cancer screening mandates and cardiovascular prevention programs. The U.S. Cancer Moonshot initiative alone earmarked over USD 1.8 billion through 2026 for early-detection infrastructure, directly boosting procurement of PET-CT combined imaging and MRI-ultrasound fusion systems [[2]](https://www.whitehouse.gov/cancermoonshot/).

A generational technology shift is underway. Legacy single-modality scanners—standalone CT, standalone PET, and conventional MRI units installed during the 2005–2015 cycle—are being replaced by multi-parametric imaging systems that deliver co-registered datasets in a single exam session. AI-overlay software now automates scan protocols, reduces average exam time by 25–30%, and lifts diagnostic confidence scores, accelerating regulatory clearances from the FDA and EMA for next-generation devices [[3]](https://www.rsna.org). Siemens Healthineers' Biograph Vision Quadra and GE HealthCare's SIGNA PET/MR exemplify this convergence, embedding deep-learning reconstruction directly into scanner hardware.

North America commands roughly 42% of the multimodal imaging market, anchored by robust Medicare/Medicaid reimbursement and widespread theranostic radiopharmaceutical adoption. Asia-Pacific is the fastest-growing region at a 7.02% CAGR, propelled by hospital modernization in China and India and expanding private healthcare investment across ASEAN. Europe holds the second-largest share at approximately 28%, led by Germany's university-hospital networks and the EU Horizon Europe research program The multimodal imaging market is positioned for sustained double-digit procurement growth in emerging economies through 2035.

## Key Report Takeaways

### • By Technology

- PET/CT systems captured 64.5% of the multimodal imaging market in 2025, reflecting entrenched oncology workflows and broad reimbursement coverage
- PET/MR systems are forecast to expand at a 6.32% CAGR through 2035, driven by neurology and cardiology demand for functional anatomical imaging
- SPECT/CT platforms generated approximately USD 0.74 billion in 2025 revenue, sustained by nuclear cardiology protocols

### • By Application

- Oncology represented 62% of the multimodal imaging market size in 2025, underpinned by PET-CT combined imaging adoption in staging and treatment monitoring
- Cardiology is projected to advance at a 7.95% CAGR to 2035, as hybrid diagnostic imaging reshapes non-invasive coronary assessment

### • By Region

- North America contributed 42% of the multimodal imaging market in 2025, led by U.S. hospital capital expenditure cycles
- Asia-Pacific is advancing at a 7.02% CAGR to 2035, with China and India accounting for over 60% of regional installations

## Market Size and Forecast (2021–2035)

MRFR's sizing model triangulates bottom-up equipment shipment data, vendor revenue filings, and top-down macroeconomic healthcare-expenditure benchmarks. Historical figures (2021–2024) reflect audited annual reports; the 2025 base year combines trailing twelve-month shipment volumes with average selling-price indices. Forecast years apply a calibrated CAGR of 5.28%, adjusted for anticipated regulatory approvals, reimbursement shifts, and technology refresh cycles in the multimodal imaging market.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Rising oncology screening mandates | 22% | Global | Short-term (≤2 yr) | [2] |
| AI-automated scan protocols | 18% | North America, Europe | Medium-term (2–4 yr) | [3] |
| Theranostic radiopharmaceutical expansion | 15% | North America | Medium-term (2–4 yr) | [7] |
| Hospital capex refresh cycles | 14% | Global | Short-term (≤2 yr) | [4] |
| Asia-Pacific healthcare infrastructure buildout | 13% | Asia-Pacific | Long-term (≥4 yr) | [6] |
| Reimbursement policy broadening for PET-CT combined imaging | 10% | North America, Europe | Medium-term (2–4 yr) | [5] |
| Photon-counting detector commercialization | 8% | Global | Long-term (≥4 yr) | [9] |

### Rising Oncology Screening Mandates

Multimodal staging scans for lung, colorectal, and head and neck cancers are now required by national cancer strategies in the US, EU member states, and China before starting treatment. In 2021, the U.S. Preventive Services Task Force extended eligibility for low-dose CT lung screening to adults aged 50–80, and within two years, follow-up PET/CT utilization increased by 18% [[2]](https://www.whitehouse.gov/cancermoonshot/). As functional anatomical imaging is incorporated into clinical guidelines, this policy-level pull guarantees that the multimodal imaging business gains from volume expansion regardless of pricing pressure.

### AI-Automated Scan Protocols

Deep-learning reconstruction methods, including Siemens' AIDAN and GE HealthCare's AIR Recon DL, improve signal-to-noise ratios and reduce MRI acquisition times by up to 50% [[3]](https://www.rsna.org). AI reduces technician burden for multi-parametric imaging systems by automating coil selection, slice positioning, and dosage optimization. AI-enabled PET/MR processes reduced the average exam time from 62 to 38 minutes, according to a 2024 RSNA study conducted across 14 U.S. sites, making hybrid diagnostic imaging financially feasible for outpatient imaging facilities [[3]](https://www.rsna.org).

### Theranostic Radiopharmaceutical Expansion

The FDA's approval of Pluvicto (Lu-177 PSMA) for metastatic castration-resistant prostate cancer in 2022 catalyzed a theranostics pipeline now exceeding 45 compounds in Phase II/III trials [[7]](https://www.novartis.com/investors). Each theranostic agent requires a companion PET-CT combined imaging scan for patient selection and response monitoring, creating a recurring-revenue tail for scanner OEMs. Novartis alone projected theranostic revenue exceeding USD 2 billion by 2025, directly tethered to multimodal imaging market demand [[7]](https://www.novartis.com/investors).

### Asia-Pacific Healthcare Infrastructure Buildout

China's 14th Five-Year Plan allocated CNY 130 billion to county-level hospital upgrades, explicitly earmarking hybrid diagnostic imaging equipment procurement for tier-2 and tier-3 cities [[6]](http://www.gov.cn). India's Ayushman Bharat Digital Mission is driving diagnostic standardization across 150,000 health-and-wellness centers, many of which will integrate MRI-ultrasound fusion platforms for point-of-care screening by 2028 [[6]](http://www.gov.cn). These government-funded programs ensure Asia-Pacific sustains the fastest growth trajectory in the multimodal imaging market through 2035.

## Restraints

## Restraints Impact Analysis

Impact percentages are directional. They reflect estimated drag on market expansion and do not mechanically subtract from the overall CAGR.

| Restraint | ~% Drag on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| High capital cost of hybrid systems | –20% | Global | Short-term (≤2 yr) | [10] |
| Radioisotope supply-chain volatility | –15% | North America, Europe | Medium-term (2–4 yr) | [11] |
| Data integration and interoperability gaps | –12% | Global | Long-term (≥4 yr) | [12] |
| Workforce shortage for advanced modalities | –10% | Global | Medium-term (2–4 yr) | [13] |
| Radiation-dose scrutiny and patient safety concerns | –8% | Europe, Asia-Pacific | Long-term (≥4 yr) | [14] |

### High Capital Cost of Hybrid Systems

A state-of-the-art PET/MR scanner carries an installed cost of USD 5–7 million, roughly three times the price of a standalone 3T MRI unit [[10]](https://www.ecri.org). For mid-size hospitals and diagnostic imaging centers in emerging economies, this upfront barrier limits procurement to grant-funded or government-subsidized purchases. Leasing and managed-equipment models partially mitigate the constraint, but they compress vendor margins and slow the multimodal imaging market's penetration into the private ambulatory segment.

### Radioisotope Supply-Chain Volatility

Six outdated research reactors provide around 80% of the world's supply of molybdenum-99, some of which are scheduled or unscheduled to go down [[11]](https://www.oecd-nea.org). Fluorine-18, which is essential for FDG-PET scans, must be close to a cyclotron and has a short half-life of 110 minutes, which limits its distribution radius. For facilities that rely on PET-CT combined imaging volume, supply disruptions undermine throughput economics by creating exam backlogs and periodically idle multi-parametric imaging systems.

### Data-Integration and Interoperability Gaps

DICOM-SR compliance, vendor-neutral archives, and significant IT expenditure are required for combining datasets from PET, MRI, CT, and ultrasound modalities into a single PACS/VNA system [[12]](https://www.himss.org). Clinical adoption of MRI-ultrasound fusion workflows is delayed by the lack of a uniform multimodal DICOM standard, and many health facilities continue to use siloed informatics stacks. The multimodal imaging market has difficulty converting installed-base expansion into clinical workflow integration unless interoperability frameworks are developed.

## Opportunities

## Multimodal Imaging Market Opportunities

### AI-Driven Quantitative Imaging Biomarkers

Regulatory pathways for software-as-a-medical-device (SaMD) are maturing, with the FDA's Digital Health Center of Excellence clearing over 950 AI/ML-enabled devices by mid-2025 [[3]](https://www.rsna.org). Companies developing quantitative imaging biomarkers—tumor heterogeneity indices, myocardial perfusion maps—can layer subscription analytics on top of existing multi-parametric imaging systems, converting one-time scanner sales into recurring SaaS revenue. This shifts the multimodal imaging market toward platform economics

### Point-of-Care MRI-Ultrasound Fusion

Compact, lower-field MRI-ultrasound fusion platforms (e.g., Hyperfine Swoop) are making functional anatomical imaging accessible outside traditional radiology departments [[8]](https://www.philips.com/healthcare). Emergency departments, rural clinics, and mobile health units represent a greenfield segment where hybrid diagnostic imaging can deliver rapid triage for stroke, musculoskeletal injury, and abdominal emergencies without patient transfer

### Emerging-Market Leasing and DaaS Models

Capital constraints in South America, the Middle East, and sub-Saharan Africa create a natural market for diagnostic-imaging-as-a-service (DaaS) and pay-per-scan leasing arrangements Vendors who bundle PET-CT combined imaging hardware with cloud-based analytics and remote technologist support can unlock USD 800 million in incremental addressable revenue by 2032, based on MRFR estimates.

### Theranostic Companion Imaging Platforms

Every approved theranostic radiopharmaceutical requires pre- and post-treatment imaging, creating a built-in demand multiplier for the multimodal imaging market [[7]](https://www.novartis.com/investors). As the Lu-177 and Ac-225 pipelines advance, scanner OEMs that co-develop validated imaging protocols with pharma partners will secure preferred-vendor status across academic medical centers

### Data Monetization via Federated Imaging Networks

Hospital consortia pooling anonymized multimodal imaging datasets for federated-learning AI training represent a nascent revenue stream [[12]](https://www.himss.org). The European Health Data Space regulation, expected to be operationalized by 2027, will create a compliant framework for cross-border imaging data sharing, potentially unlocking licensing fees that flow back to imaging departments investing in multi-parametric imaging systems

## Future Outlook

## Multimodal Imaging Market Future Outlook

### AI-Autonomous Imaging Workflows

By 2030, autonomous scan-orchestration engines will manage end-to-end PET-CT combined imaging sessions—from patient positioning through reconstruction and preliminary reporting—with minimal technologist intervention [[3]](https://www.rsna.org). The multimodal imaging market will shift from hardware-centric revenue toward recurring AI-license fees, mirroring the software-defined transformation in adjacent diagnostic sectors. A recent study projects that AI-driven imaging analytics will represent a USD 4.5 billion standalone software segment by 2032, with hybrid platforms capturing the largest share [[3]](https://www.rsna.org).

### Theranostic-Imaging Convergence

The radioligand-therapy pipeline—spanning prostate, neuroendocrine, breast, and gastric cancers—will expand the multimodal imaging market's addressable use-case portfolio by an estimated 30–40% over the next decade [[7]](https://www.novartis.com/investors). Each new indication approved will require companion hybrid diagnostic imaging scans for patient stratification and longitudinal response assessment, creating a durable demand floor linked to pharmaceutical rather than capital-equipment cycles.

### Photon-Counting and Spectral Detector Adoption

Photon-counting CT detectors, commercialized by Siemens Healthineers (NAEOTOM Alpha) and under development by GE and Philips, deliver spectral material-decomposition data natively, blurring the line between CT and hybrid modalities [[9]](https://www.siemens-healthineers.com). By 2033, spectral CT integration into PET-CT combined imaging platforms will enhance tissue characterization without additional scan time, strengthening the clinical value proposition of multi-parametric imaging systems and driving premium pricing in the multimodal imaging market.

### Sustainability and Circular-Economy Pressures

ESG mandates from the EU Green Deal and U.S. SEC climate-disclosure rules will push scanner OEMs to adopt modular, upgradable architectures that extend equipment lifespans from 10 to 15+ years [[14]](https://ec.europa.eu). Refurbished and remanufactured PET/CT systems—already a USD 600 million subsegment—will gain legitimacy in procurement tenders, creating a secondary multimodal imaging market that serves cost-sensitive buyers while reducing electronic-waste streams.

## Segment Insights

## Multimodal Imaging Market Segmentation

### By Technology

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| PET/CT Systems | 64.5% share (2025) | Oncology staging and restaging protocols |
| SPECT/CT Systems | USD 0.74 Billion (2025) | Nuclear cardiology perfusion imaging |
| PET/MR Systems | 6.32% CAGR (2026–2035) | Neurology and pediatric imaging demand |
| Others | USD 0.18 Billion (2025) | Optical-CT fusion research platforms |

PET/CT systems dominate the multimodal imaging market because oncology—the largest application—relies on FDG-PET for metabolic staging. Installed-base inertia, extensive clinical evidence libraries, and established reimbursement codes reinforce PET-CT combined imaging as the default hybrid platform. PET/MR systems, while growing fastest, remain constrained by higher capital costs and the need for specialized MR-compatible PET detectors; adoption clusters in academic medical centers conducting neurology and functional anatomical imaging research.

SPECT/CT maintains a stable footprint in nuclear cardiology, where Tc-99m perfusion imaging remains the standard of care. However, the segment faces gradual share erosion as PET-based cardiac tracers (Rb-82, N-13 ammonia) gain reimbursement traction, pushing cardiologists toward hybrid diagnostic imaging platforms with superior quantitative accuracy.

### By Application

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Oncology | 62% share (2025) | Mandatory staging scans per NCCN guidelines |
| Cardiology | 7.95% CAGR (2026–2035) | Non-invasive coronary-flow-reserve assessment |
| Neurology | USD 0.34 Billion (2025) | Alzheimer's and epilepsy pre-surgical workup |
| Ophthalmology | 4.65% CAGR (2026–2035) | OCT-angiography fusion platforms |
| Musculoskeletal Disorders | USD 0.14 Billion (2025) | PET/MR for inflammatory arthritis monitoring |
| Others | 4.20% CAGR (2026–2035) | Infectious disease and transplant imaging |

Oncology's grip on the multimodal imaging market stems from guideline-driven utilization: NCCN protocols mandate PET/CT for initial staging in lung, lymphoma, head-and-neck, and melanoma cases. Cardiology is emerging as the highest-growth application, as MRI-ultrasound fusion and PET-based myocardial-perfusion imaging replace invasive catheterization for intermediate-risk patients.

### By End User

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Hospitals | 75% share (2025) | Capital budgets, in-house radiology departments |
| Diagnostic Imaging Centers | 6.55% CAGR (2026–2035) | Outpatient shift, DaaS models |
| Others | USD 0.12 Billion (2025) | Research institutions, mobile imaging units |

Hospitals command the largest share of the multimodal imaging market due to the capital intensity and clinical-support requirements of hybrid scanners. Diagnostic imaging centers represent the fastest-growing end-user segment, propelled by the outpatient migration trend and managed-equipment leasing models that lower entry barriers for multi-parametric imaging systems procurement.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric | Primary Investment Themes |
| --- | --- | --- |
| North America | 42% share (2025) | Theranostics, AI analytics, replacement cycles |
| Europe | 28% share (2025) | EU MDR compliance, Horizon Europe grants |
| Asia-Pacific | 7.02% CAGR (2026–2035) | Hospital buildout, chronic-disease burden |
| South America | USD 0.23 Billion (2025) | DaaS leasing, oncology access programs |
| Middle East & Africa | 5.65% CAGR (2026–2035) | Vision 2030 health investment, PPP models |
| Total | USD 4.60 Billion (2025) | — |

The multimodal imaging market exhibits clear regional asymmetry: mature markets dominate installed base and revenue, while high-growth economies drive volume expansion. North America and Europe together account for roughly 70% of global revenue, yet Asia-Pacific's trajectory—fueled by hospital modernization and chronic-disease epidemiology—will reshape the competitive landscape by 2035.

### North America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| US | 78% of regional share | Medicare PET reimbursement expansion [5] |
| Canada | 5.85% CAGR | Provincial cancer-agency hybrid diagnostic imaging upgrades [15] |
| Mexico | USD 0.09 Billion (2025) | INSABI hospital modernization program [16] |

The U.S. dominates the multimodal imaging market in North America through a combination of deep reimbursement, a robust theranostic radiopharmaceutical pipeline, and strong academic-medical-center demand for PET/MR research platforms. CMS expanded outpatient PET-CT combined imaging coverage for Alzheimer's diagnosis in 2024, adding an estimated 180,000 incremental scans annually [[5]](https://www.cms.gov). Canada's multi-provincial cancer-agency framework has accelerated PET/CT procurement, while Mexico is leveraging public–private partnerships to install hybrid systems in underserved states.

### Europe

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Germany | 24% of regional share | University-hospital research consortia [17] |
| UK | 5.48% CAGR | NHS long-term plan imaging investment [18] |
| France | USD 0.16 Billion (2025) | Plan France 2030 health innovation fund [19] |
| Italy | 4.92% CAGR | PNRR-funded hospital digitalization [20] |
| Spain | USD 0.10 Billion (2025) | Regional health authority procurement cycles |
| Nordic Countries | 5.15% CAGR | National precision-medicine programs |
| Russia | USD 0.07 Billion (2025) | Federal oncology infrastructure projects |
| Rest of Europe | 4.70% CAGR | EU cohesion fund hospital modernization |

Europe's multimodal imaging market benefits from centralized procurement models and strong clinical-trial ecosystems. Germany anchors regional revenue through its dense university-hospital network, where functional anatomical imaging research attracts Horizon Europe grants exceeding EUR 400 million earmarked for medical-imaging AI [[17]](https://www.dfg.de). The UK's NHS committed GBP 2.3 billion to diagnostic capacity expansion under its 2024 Imaging Networks program, prioritizing MRI-ultrasound fusion and PET/CT upgrades across community diagnostic centers [[18]](https://www.england.nhs.uk).

### Asia-Pacific

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| China | 38% of regional share | 14th Five-Year Plan hospital upgrades [6] |
| India | 8.15% CAGR | Ayushman Bharat digital diagnostic mandate [6] |
| Japan | USD 0.21 Billion (2025) | Society 5.0 medical robotics integration |
| South Korea | 6.85% CAGR | National Cancer Center expansion |
| ASEAN | USD 0.11 Billion (2025) | Private hospital investment, medical tourism |
| Rest of Asia-Pacific | 6.40% CAGR | Government-subsidized screening programs |

Asia-Pacific represents the fastest-growing segment of the multimodal imaging market, propelled by China's county-hospital upgrade cycle and India's push for standardized diagnostic infrastructure. China installed over 320 new PET/CT systems in 2024, with tier-2 cities accounting for 45% of placements [[6]](http://www.gov.cn). India's private hospital chains—Apollo, Fortis, Max Healthcare—are deploying multi-parametric imaging systems to differentiate premium oncology and cardiology service lines, while ASEAN markets attract cross-border medical-tourism patients seeking advanced hybrid diagnostic imaging.

### South America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Brazil | 58% of regional share | SUS oncology network expansion [21] |
| Argentina | 5.10% CAGR | Public-hospital imaging fleet renewal |
| Rest of South America | USD 0.04 Billion (2025) | NGO-funded screening programs |

Brazil's Unified Health System (SUS) has prioritized PET-CT combined imaging installation across federal cancer institutes, adding 28 new PET/CT units between 2022 and 2024 [[21]](https://www.gov.br/saude). Argentina's provincial health systems are renewing aging gamma-camera fleets with SPECT/CT platforms, while smaller markets rely on mobile imaging partnerships and donor-funded screening initiatives to access the multimodal imaging market.

### Middle East & Africa

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 32% of regional share | Vision 2030 health infrastructure [22] |
| UAE | 5.90% CAGR | Medical-tourism hub strategy |
| South Africa | USD 0.03 Billion (2025) | National Health Insurance pilot |
| Egypt | 5.45% CAGR | Universal health coverage rollout |
| Rest of MEA | USD 0.04 Billion (2025) | PPP diagnostic center expansion |

Saudi Arabia's Vision 2030 has committed over USD 65 billion to healthcare infrastructure, with flagship projects like NEOM Health embedding PET/MR and advanced functional anatomical imaging into greenfield hospital designs [[22]](https://www.vision2030.gov.sa). The UAE leverages its medical-tourism positioning to justify premium multi-parametric imaging systems procurement, while South Africa's NHI pilot is expected to channel public funds toward hybrid diagnostic imaging access in underserved provinces.

## Competitive Benchmarking

## Competitive Benchmarking

The multimodal imaging market exhibits moderate concentration, with the top five vendors capturing an estimated 68–72% of global revenue. The Herfindahl-Hirschman Index (HHI) sits in the 1,800–2,200 range, reflecting a market led by three tier-one OEMs—GE HealthCare, Siemens Healthineers, and Philips—flanked by specialized challengers in [nuclear medicine](https://www.marketresearchfuture.com/reports/nuclear-medicine-market-6674) and emerging AI analytics firms. Cloud-based analytics platforms are increasingly the battleground for differentiation, as hardware specifications converge.

| Company | Est. Revenue Share Range | Key Offerings | Strategic Positioning |
| --- | --- | --- | --- |
| GE HealthCare | 18–22% | Discovery MI, SIGNA PET/MR, AIR Recon DL | Full-portfolio hybrid imaging with AI analytics |
| Siemens Healthineers | 20–24% | Biograph Vision Quadra, NAEOTOM Alpha, syngo.via | Photon-counting leadership, cloud-based PACS |
| Philips | 12–16% | Vereos Digital PET/CT, MR-guided interventions | Integrated diagnostics-to-therapy pathways |
| Canon Medical Systems | 5–8% | Cartesion Prime PET/CT, Vantage Centurian MRI | Cost-competitive solutions for mid-tier hospitals |
| United Imaging Healthcare | 4–7% | uMI Panorama, uExplorer total-body PET/CT | Price-disruptive total-body PET-CT combined imaging |
| Bruker Corporation | 2–4% | Preclinical PET/MR, Albira Si | Research-grade multi-parametric imaging systems |
| Mediso Medical Imaging | 1–3% | AnyScan TRIO SPECT/CT/PET | Flexible triple-modality nuclear medicine |
| Spectrum Dynamics Medical | 1–2% | VERITON-CT digital SPECT/CT | CZT-based cardiac hybrid diagnostic imaging |
| Subtle Medical | 1–2% | SubtlePET, SubtleMR AI enhancement | AI dose-reduction and scan-acceleration software |
| Positron Corporation | <1% | Attrius PET/CT | Compact PET-CT combined imaging for community hospitals |

## Recent News & Developments

## Recent News & Developments

- Philips (September 2024): Partnered with Elekta to integrate PET/MR imaging data into MR-Linac radiotherapy planning, advancing multi-parametric imaging systems use in adaptive radiation therapy [[8]](https://www.philips.com/healthcare).
- U.S. CMS (June 2024): Finalized expanded Medicare coverage for amyloid PET-CT combined imaging in Alzheimer's diagnosis, adding an estimated 180,000 reimbursable scans annually to the multimodal imaging market [[5]](https://www.cms.gov).

## Report Scope

## Multimodal Imaging Market Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global multimodal imaging market — hardware, software, and associated services |
| Study Period | 2021–2035 |
| CAGR | 5.28% (2026–2035) |
| Base Year Size | USD 4.60 Billion (2025) |
| Forecast Endpoint | USD 7.58 Billion (2035) |
| Fastest Growing Segment | PET/MR Systems (by technology); Cardiology (by application); Asia-Pacific (by region) |
| Companies Profiled | GE HealthCare, Siemens Healthineers, Philips, Canon Medical, United Imaging, Bruker, Mediso, Spectrum Dynamics, Subtle Medical, Positron Corp. |
| Valuation Currency | USD Billion |

## Frequently Asked Questions

**Q: How does PET/MR compare to PET/CT for soft-tissue oncology staging?**
A: PET/MR delivers superior soft-tissue contrast without ionizing CT radiation, making it preferred for liver, pelvic, and pediatric tumors. However, PET/CT remains faster and more cost-effective for routine lung and lymphoma staging [10].

**Q: What financing structures help smaller facilities afford hybrid scanners?**
A: Managed-equipment agreements, pay-per-scan leasing, and vendor-backed revenue-sharing models reduce upfront capital requirements to near zero. These structures now account for roughly 30% of new PET/CT placements globally [23].

**Q: How do radioisotope shortages affect multimodal imaging market operations?**
A: Reactor shutdowns can idle PET scanners for days, forcing referral diversions. Facilities mitigate risk through dual-supplier contracts and on-site cyclotron investment, though cyclotrons add USD 2–3 million in capital cost [11].

**Q: Which AI regulatory pathway applies to multimodal imaging software?**
A: The FDA's De Novo and 510(k) pathways cover most AI-enabled imaging algorithms, while the EU requires MDR Class IIa/IIb conformity assessment. Predicate-device availability determines U.S. pathway selection [3].

**Q: What role does photon-counting CT play in the multimodal imaging market's evolution?**
A: Photon-counting detectors enable spectral material decomposition natively, reducing the need for separate contrast-phase acquisitions. Integration into PET/CT platforms will enhance tissue characterization without additional scan time [9].

**Q: How are reimbursement policies evolving for MRI-ultrasound fusion procedures?**
A: U.S. CPT codes for MRI-ultrasound fusion-guided prostate biopsy gained full Medicare coverage in 2023, and similar codes are under review for breast and liver applications. European reimbursement varies by country [5].

**Q: What cybersecurity risks affect networked multimodal imaging market installations?**
A: Connected scanners are vulnerable to ransomware and data exfiltration via unpatched DICOM interfaces. The FDA's 2023 Refuse-to-Accept policy now mandates cybersecurity documentation for all new device submissions [12].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/multimodal-imaging-market-41061*